Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment

Journal of Clinical Pharmacology

Volumn 38, Issue 2, 1998, Pages 129-137

  Martin, David E ^a   Chapelsky, Martha C ^b   Ilson, Bernard ^a   Tenero, David ^b   Boike, Steven C ^a   Zariffa, Névine ^a   Jorkasky, Diane K ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPROSARTAN; PLASMA PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0031882169     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04401.x     Document Type: Article

References (18)

1. Brooks DP, DePalma PD, Fredrickson TA, Spielman WS, Ruffolo RR: Nonpeptide angiotensin II receptor antagonists: potential advantages over ACE inhibitors. Proc West Pharmacol Soc 1993;36:25-28.
2. Duncia JV, Chiu AT, Carini, DJ, Gregory GB, Johnson AL, Price WA, et al: The discovery of potent non-peptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Chem 1990;33:1312-1329.
3. Weinstock J, Keenan RM, Samanen J, Hempel J, Finkelstein JA Franz RG, et al: 1-(carboxy-benzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 1991;34:1514-1517.
4. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, et al: Pharmacological characterization of the non-peptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260:175-181.
5. Brooks DP, Fredrickson TA, Weinstock J, Ruffolo RR, Edwards RM, Gellai M: Antihypertensive activity of the non-peptide angiotensin II receptor antagonist. SK&F 108566, in rats and dogs. Arch Pharmacol 1992;345:673-678.
6. Ilson B, Boike S, Freed, M, Everitt D, Brown L, Zariffa N, Jorkasky D: Renal hemodynamic effects of SK&F 108566, a non-peptide selective angiotensin (AII) receptor AT1 antagonist (abstract). Clin Pharmacol Ther 1994;55:206.
7. White WB, Mansoor GA, Lessem J, Shusterman N: Evaluation of the angiotensin II receptor antagonist, eprosartan, by casual and ambulatory BP monitoring (abstract). Clin Res 1994;42;447A.
8. Cox PJ, Bush BD, Gorycki PD, Kuo GY, Kenworthy D, Law DW, et al: The metabolic fate of eprosartan in healthy subjects. Exp Toxicol Pathol 1996;48(Suppl II):75-82.
9. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Lundberg DE, Person CR, Knox S, Cyronak M: Determination of SK&F 108566 in human plasma by solid-phase extraction cleanup and reversed-phased high performance liquid chromatography. J Chromatogr (in press).
11. Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level time curve. J Pharmacokinet Biopharm 1978;6:539-547.
12. Cook RD: Detection of influential observations in linear regression. Technometrics 1977;19:15-18.
13. Cook RD: Influential observations in linear regression. J Am Stat Assoc 1979;74:169-174.
14. Matzke GR, Millikin SP: Influence of renal function and dialysis on drug disposition. In, Evans WE, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Third edition. Vancouver: Applied Therapeutics, 1992;1-49.
15. Rowland M, Tozer T: Clinical Pharmacokinetics: Concepts and Applications. Second edition. Philadelphia: Lea & Febiger, 1989.
16. Reidenberg MM: The binding of drugs to plasma proteins from patients with poor renal function. Clin Pharmacokinet 1976: 1:121-125.
17. Odar-Cederlof I, Borga O: Impaired protein binding of phenytoin in uremia and displacement effects of salicylic acid. Clin Pharmacol Ther 1976;20:36-47.
18. Odar-Cederlof I, Borga O: Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol 1974;7:31-37.